Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 2/3 trial of trifluridine/tipiracil plus bevacizumab vs irinotecan-based regimens plus bevacizumab as second-line therapy in metastatic colorectal cancer
jRCT1080223562Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of trifluridine + tipiracil in metastatic colon cancer (mCRC), Colon adenocarcinoma and rectal adenocarcinoma (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Started Jun 2017; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
metastatic colon cancer (mCRC)Colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on jRCT1080223562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223562.